Acquisition of Theravia from Mérieux Equity Partners represents meaningful step forward in Norgine’s strategy for sustainable growth, adding a complementary portfolio of rare disease medicines

Transaction further establishes Norgine’s position as a partner of choice for commercialising rare and specialty pharmaceuticals in Europe

PARIS, April 17, 2025 /PRNewswire/ — Norgine and Theravia announced today that they have entered into a definitive agreement under which Norgine will acquire Theravia, an international pharmaceutical company specialising in cutting-edge treatments for patients with rare and debilitating conditions.

Recent deals with Fennec Pharma for PEDMARQSI^® and X4 Pharma for mavorixafor demonstrate Norgine’s strong emphasis on driving growth in rare disease and specialty medicines through acquisitions and in-licensing.

Theravia’s innovations have resulted in successful launches of life-saving medications which have changed patient outcomes worldwide. Theravia has several products in the rare disease space, including SIKLOS^®, for adults and children with sickle cell disease, and ORPHACOL^®, a medicine for adults and children who have a genetic disorder that affects bile production by the liver. These products span both the rare haematology and rare hepatology therapeutic areas and are complementary to Norgine’s existing rare and specialty portfolio. The development of Theravia in the past few years has been supported by its majority shareholder Mérieux Equity Partners, a healthcare dedicated investment firm based in France.

“This acquisition is a unique opportunity for Norgine to bolster our growth trajectory, as well as our rare disease portfolio.” said Janneke van der Kamp, Chief Executive Officer, Norgine. “With our strong legacy and proven track record of successfully bringing innovative treatments to patients, we believe we are well placed to ensure the Theravia medicines reach their full potential.”

Franck Hamalian, Chief Executive Officer, Theravia, added: “The joining of our companies brings together the skills, know-how and geographical presence that will create a European-based champion of rare and ultra rare disease. Our combined product portfolios and Norgine’s legacy and experience will enable broader access to medicines for patients with high unmet medical needs.”

With the acquisition of Theravia, Norgine will now have six core products in its rare disease portfolio (PEDMARQSI^®, eflornithine, mavorixafor, AGILUS^®, SIKLOS^® and ORPHACOL^®) thereby comprising a franchise of critical scale with the ability to be a key growth driver in the medium-to-long-term.

Norgine looks forward to building on this transaction as we continue to strengthen our platform for future acquisitions and in-licensing opportunities to drive growth.

The transaction remains subject to obtaining customary regulatory approvals from the competent authorities.

Notes

About Theravia
Theravia is an international pharmaceutical laboratory specializing in rare or neglected diseases. Formed through the merger of Addmedica and CTRS, Theravia is dedicated to addressing the unmet medical needs of patients with these challenging conditions.

About SIKLOS^®
SIKLOS^® is used in adults, adolescents and children over two years of age who have sickle-cell syndrome, a genetic disease where the red blood cells become rigid and sticky and change from being disc-shaped to being crescent-shaped (like a sickle). It is used to prevent recurrent, painful vaso-occlusive crises that happen when blood vessels become blocked by the abnormal red blood cells, restricting the flow of blood to an organ. They can include acute chest syndrome, a life-threatening condition when the patient has sudden chest pain, fever, hard breathing or signs of fluid in the lungs on an X-ray.

SIKLOS^® is marketed in 17 countries around the world.

About ORPHACOL^®
ORPHACOL^® is a medicine containing cholic acid, a substance found in the bile, which is used to digest fats. It is approved in the US and Europe used to treat adults and children from one month of age who have a genetic abnormality that makes them unable to produce bile. The therapy is used in patients who do not have enough of two specific liver enzymes which makes their liver unable to produce enough of the main components of bile, called primary bile acids, such as cholic acid. When these primary bile acids are lacking, the body produces abnormal bile acids instead which can damage the liver, potentially leading to life-threatening liver failure.

ORPHACOL^® is marketed in 23 countries around the world.

About PEDMARQSI^®
PEDMARQSI^® is a novel formulation of anhydrous sodium thiosulfate, specifically developed and manufactured for the prevention of cisplatin-induced hearing loss in patients 1 month to <18 years of age. It is the first and only preventative treatment developed for cisplatin-induced ototoxicity to support children and adolescent patients with localised, non-metastatic solid tumour cancers.

It was granted marketing authorisation by the EMA in May 2023 (under the paediatric-use marketing authorisation (PUMA) programme) and the MHRA in October 2023.

About Mavorixafor
Mavorixafor is a selective CXCR4 receptor antagonist approved in the U.S. and marketed by X4 as XOLREMDI^®, an oral, once-daily treatment for patients 12 years of age and older with WHIM syndrome, a rare primary immunodeficiency.

In January 2025, X4 submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for mavorixafor for the treatment of WHIM syndrome, for which it has been granted Orphan Drug Designation by both the EMA and the U.S. Food and Drug Administration.

X4 is also developing the medicine to treat chronic neutropenia (CN) and is currently conducting a global, pivotal Phase 3 clinical trial in certain CN disorders. Norgine has responsibility for commercialisation in Europe, Australia, and New Zealand following regulatory approvals.

About Eflornithine
Eflornithine has been investigated for use as a post maintenance treatment for high-risk neuroblastoma (HRNB) in paediatric patients with no active disease (NAD) / no evidence of disease (NED) after first line multiagent, multimodality therapy. It is a targeted therapy that blocks an enzyme called ornithine decarboxylase (ODC), responsible for producing polyamines, which are important to tumour growth and development.

The medicine is approved by the FDA for a maintenance therapy for high-risk neuroblastoma in adult and pediatric patients. In April 2024, an application for approval was submitted by Norgine for the use of eflornithine in high-risk neuroblastoma (HRNB), via Project Orbis in Australia, Switzerland and the United Kingdom. In January 2025, a marketing authorisation application was filed to the European Medicines Agency (EMA) for the medicine in high-risk neuroblastoma (HRNB).

About AGILUS®
AGILUS^® is a medicine used to treat malignant hyperthermia (rapid rise in body temperature caused by uncontrolled muscle contractions) in adults and children. Malignant hyperthermia is a serious reaction to certain medicines used for general anaesthesia during surgery or other medical procedures.

AGILUS^® is approved for use by the EMA for for the treatment of malignant hyperthermia in adults and children in combination with adequate support measures.

About Mérieux Equity Partners
Founded in 2009, Mérieux Equity Partners (“MxEP”) is a leading European healthcare-specialized investment firm, with two dedicated platforms, Venture Capital and Buyout, supporting companies ranging from start-ups to established leaders. Benefiting from a longstanding expertise and a large network, MxEP invests in companies with ambitious growth projects and transformative products or services in healthcare. MxEP is AMF-accredited and currently manages c.€1.5bn of AuM.

About Norgine
Norgine is a uniquely positioned, specialty pharmaceutical and consumer healthcare company, with over €550 million of annual revenues and a 120-year track record of bringing life-changing products to patients and consumers across our core markets of Western Europe, Australia and New Zealand.

Norgine’s integrated approach – strong commercial capabilities, as well as deep medical, regulatory and clinical expertise, in-house manufacturing, robust supply networks, and best-in-class enabling functions – ensures that Norgine can deliver high-quality, transformative medicines quickly and effectively to over 25 million patients annually.

Norgine is a nimble, innovative, and high-performing company that has been transformed by a relentless focus on operational excellence. This focus will enable us to secure the legacy of more than a century of innovation and doing the right thing by our patients, as we push the boundaries and take strides into therapeutic innovation.

NORGINE and the sail logo are trademarks of the Norgine group of companies.

SEOUL, South Korea, April 17, 2025 /PRNewswire/ — Korean skincare favorite Fation, the top-rated trouble-care brand at Olive Young with a near-perfect 4.9/5.0 rating, has officially launched in the U.S. market. Next rookie following after its best selling ‘Trouble’ Line, the Nosca9 Deep Pore Cleansing Foam, hit Amazon in March—and the response has been immediate. Named an Amazon “Overall Pick” and boasting an average rating above 4.7 stars, the product is already gaining momentum among beauty enthusiasts looking to achieve the Korean “glass skin” look.

What sets this cleanser apart is its key ingredient: Retinal—a highly functional next-generation powerhouse often described as a more effective and less irritating upgrade to the widely known Retinol. Rare to use on the cleanser category but backed by the unique technology of Dong-A Pharmaceutical, a leading name in Korea’s pharmaceutical industry for over 94 years, Fation’s proprietary Nano-Retinal RX Complex™ delivers visible pore-tightening benefits with dermatologist-grade precision.

In addition to Retinal, the formula includes rice extract, 17 types of amino acids, and a tannin complex for a well-rounded, skin-friendly deep cleanse. The unique, stretchy texture clings to impurities and excess oil, helping to refine skin texture and minimize enlarged pores.

In celebration of its successful U.S. debut, Fation is offering a limited-time Amazon promotion from April 14 to 23, slashing the price from $15.99 to $11.19 (30% Off).

The Nosca9 line is just the beginning. Fation’s Trouble Soothing range—including toner, serum, cream, and masks for sensitive or acne-prone skin—is also available on Amazon.

Explore the full collection:
Cleansing Foam: https://amzn.to/44vKTGi
Serum Set: https://amzn.to/3EfyVpP
Cream S: https://amzn.to/4lsXVuf
Toner S: https://amzn.to/42cCzKk
Real Fit Mask: https://amzn.to/4ju9AY1
Glass skin starts here—with Fation.

AUCKLAND, New Zealand, April 17, 2025 /PRNewswire/ — Creality, a global leader in the 3D printing industry, brought its community event ShareFest back to “the city of sails” of Auckland and attracted more than 100 people to celebrate this yearʼs theme — “To Makers. By Makers.”

A Festival of Multi-layered Fun

The 2025 fan gathering in New Zealand is a joint effort by Creality and PB Tech — one of Australasia’s largest computing and technology resellers.

At the event, Creality showcased its latest innovations — K2 Plus, Creality Hi, Ender-5 Max, Falcon A1, and the new slicer software Creality Print 6.0. Apart from an exclusive product hands-on experience, the community members participated in interactive games like a quick quiz that included a variety of 3D printing questions, and the “Make & Match” to assemble a 3D printed Creality logo. The event also saw inspiring speeches from invited industry experts, along with an open discussion where everyone was encouraged to share everything about their experience with 3D printing. Last but not least, the event culminated in the 3D printed model contest where all makersʼ creativity shines the brightest.

Powerful Industry Insights

Invited speakers from vastly different fields shared their takes on how 3D printing has made a huge difference in both their professions and hobbies.

• Carl Salas — Lecturer at the Unitec School of Architecture
  Carl shared how 3D printing is rapidly changing the landscape of architectural design, cultivating architects with the mindset to think outside the box.
• H + R Drone Racing — Drone Lovers & Content Creators
  The drone-loving twins started a YouTube channel to document their DIY projects — from RC submarines, drones and FPVs to an RC wingsuit. Fueled by a passion for turning out-of-this-world ideas into reality, they’ve brought many maker projects to life.

Model Contest Highlights

With over 20 models vying for 3 top spots, this year’s contest was intense. Meet the winners:

1. 1st Place: R2-D2 by John Ferguson
   John won with his 365-day project — a remote-controlled, talking R2-D2 from Star Wars, printed all on a Creality Ender-5.
2. 2nd Place: Yarn Tools by Terri Cattell
   A retiree, grandma, and ShareFest second-timer, Terri got a K1 Max printer as a gift just last year, and amazed everybody at the event with her 3D printed yarn swift — a combination of her long-time and new-found hobbies.
3. 3rd Place: BB-8 & EVE by Mike Owen
   A 1:1 BB-8 replica that is fully animatronic.

Incredible Energy from Makers

The ShareFest is held at the PB Tech store in Manukau, located in the suburb of Auckland, where product manager Joe Shi expressed his excitement:

“The energy today was incredible — far beyond what we imagined! Seeing so many passionate makers, from veteran creators like John to inspiring newcomers like Terri, reminds us why we do this. Together with Creality, we’re proud to foster a culture where ‘By Makers. To Makers’ comes to life. The feedback has been overwhelming, and we can’t wait to bring even more innovation to our next ShareFest!”

About Creality

Founded in Shenzhen in 2014, Creality is a global pioneer in the 3D printing industry that focuses on the research, design, and production of consumer and professional-grade 3D printers and 3D printing accessories. ShareFest is a global community event hosted by Creality.

Creality has officially launched an Instagram account dedicated to 3D printing hobbyists in New Zealand & Australia. Follow creality_anz to know more. 
https://www.instagram.com/creality_anz/

Media contact: brand@creality.com

NEW YORK, April 17, 2025 /PRNewswire/ — As spring blooms across the country, so does allergy season — a time when pollen, dust, and airborne irritants can aggravate respiratory conditions and make breathing more difficult. VARON, a leading provider of respiratory care solutions, is helping consumers combat these seasonal challenges with advanced oxygen concentrators and exclusive spring savings.

To support customers during peak allergy season, VARON has launched its Spring Sale, offering sitewide discounts of up to 30% on select oxygen concentrators and accessories. The promotion is aimed at helping more people access reliable respiratory support while enjoying significant savings.

How Spring Allergies Affect Breathing

Each year, millions of Americans experience allergic rhinitis, commonly known as hay fever. For individuals living with asthma, chronic obstructive pulmonary disease (COPD), or other respiratory conditions, exposure to spring allergens can worsen symptoms such as wheezing, congestion, and shortness of breath.

Oxygen therapy has become a trusted solution for improving respiratory health, ensuring users receive adequate oxygen while reducing exposure to airborne allergens.

VARON Oxygen Concentrators: Breathing Easier This Spring

VARON’s oxygen concentrators are engineered with advanced filtration systems to deliver purified oxygen while minimizing irritants. Key features include:

• Enhanced Air Filtration: Removes pollen, dust, and other allergens from the air.
• Built-in Humidification: Adds moisture to oxygen to prevent dryness and irritation.
• Continuous and Pulse Flow Options: Customized oxygen delivery for every need.
• Portable, Lightweight Design: Ideal for users staying active indoors or outdoors.

These healthcare devices offer a convenient solution for individuals seeking respiratory support at home or on the go.

Spring into Savings: Limited-Time Discounts Now Available

In celebration of spring, VARON’s Spring Sale offers exclusive savings to help more customers access essential respiratory care solutions.

Customers can take advantage of:

• Up to 30% off on featured oxygen concentrators and respiratory accessories
• 18% off sitewide with no code required
• Free shipping on all orders

Whether planning outdoor adventures, family gatherings, or simply enjoying fresh air in comfort, VARON’s oxygen concentrators help users breathe easier and embrace the season.

For more details on VARON’s Spring Sale or to explore its oxygen therapy solutions, visit https://varoninc.com or contact support@varoninc.com.

Essential Maintenance Tips for Optimal Performance and Hygiene

In addition to the promotions, VARON is encouraging customers to take this opportunity to care for their oxygen equipment. “Regular maintenance of oxygen devices and accessories plays a vital role in ensuring safe, effective, and comfortable oxygen therapy,” said Dr. Walkers, Director of Product Development at VARON. “Over time, components like filters and cannulas can accumulate dust, moisture, and bacteria, which may affect both air quality and the overall user experience.”

VARON recommends the following spring maintenance checklist:

1. Replace Air Filters

Filters help block dust, debris, and airborne particles from entering the device. Replacing them every 3 months (or more frequently in dusty environments) ensures clean air intake and protects internal components.

2. Change Nasal Cannulas and Tubing

These components are in direct contact with the user and can harbor bacteria if not changed regularly. It is recommended to replace cannulas every 2-4 weeks, based on your frequency of use, to maintain hygienic oxygen delivery.

3. Clean Accessories Weekly

Wash cannulas, tubing, and humidifier bottles (if applicable) weekly using mild soap and warm water, then allow them to air dry completely. Never use harsh chemicals or alcohol.

4. Inspect and Replace Batteries (for Portable Units)

If using a portable concentrator, check battery life and replace older batteries that no longer hold a full charge. Proper battery function is essential for uninterrupted oxygen therapy on the go.

5. Store Devices Properly

Keep equipment in a clean, dry place when not in use. Avoid direct sunlight, excessive heat, or moisture to prevent internal damage and preserve the unit’s integrity.

Customers can find replacement filters, cannulas, tubing, and batteries available at discounted prices during the Spring Sale.

Supporting Health and Wellness Year-Round

In addition to providing high-quality respiratory equipment, VARON encourages customers to take proactive steps to manage allergy symptoms during spring. These include using air purifiers indoors, limiting outdoor exposure during peak pollen hours, staying hydrated, and consulting healthcare providers for personalized care plans.

VARON remains committed to supporting respiratory wellness with products designed for comfort, efficiency, and reliability.

About VARON

VARON is a trusted leader in respiratory care, providing innovative oxygen therapy solutions to support individuals with chronic and seasonal breathing difficulties. Committed to comfort, reliability, and cutting-edge technology, VARON helps users around the world breathe easier every day.

Media Contact:
Winnie Li
official@varoninc.com 

New data from Best Lawyers reveals top-ranked legal talent across Australia, providing insights for firm marketing and recruitment

AUGUSTA, Ga., April 17, 2025 /PRNewswire/ — Best Lawyers® today announces the release of the 2026 editions of The Best Lawyers in Australia™ and Best Lawyers: Ones to Watch in Australia™, offering law firms a powerful resource to benchmark professional excellence, spotlight emerging legal talent and strengthen their competitive standing.

2026 editions of The Best Lawyers in Australia™

The Best Lawyers rankings, representing the country’s top 5% of legal talent¹, offer data-driven insights and access to a global network that Australian legal firms can leverage to support their marketing, recruitment and client development initiatives.

Best Lawyers CEO, Phillip Greer, said the 18th edition of The Best Lawyers in Australia recognises more than 4,500 lawyers selected from a rigorous peer-review process. Of those, 314 lawyers are being honoured for the first time, reflecting the continued expansion in this region.

Now in its fourth year, Best Lawyers: Ones to Watch in Australia highlights more than 790 early-career lawyers for outstanding professional achievement.

In addition, 329 nominees were awarded the prestigious “Lawyer of the Year” title, for those receiving the highest overall peer feedback for a specific practice area and geographic region.

“The Australian legal market continues to advance, with seasoned lawyers and emerging voices leading the charge on some of the globe’s most pressing legal challenges,” Mr Greer said.

“From class actions and data privacy to climate-related litigation, this year’s Australian honorees represent the highest calibre of the profession, with a growing focus on impact, innovation and accountability.”

Sydney and Melbourne dominance challenged

Sydney, Melbourne and Brisbane lead the country in awarded talent, underscoring their roles as Australia’s primary legal and commercial hubs – but there are emerging trends as to where top legal talent is concentrated, according to Best Lawyers Vice President of Research and Development, Elizabeth Petit.

“Brisbane has emerged as a growing hub, attracting a rising number of high-performing legal professionals – likely driven by the city’s population growth, economic development and expanding legal market.

“Sydney and Melbourne maintain their long-standing reputations as powerhouses for top legal talent, however their growth has not been as dramatic,” she said.

Litigation remains the most recognised practice area in the 2026 editions, followed by Insurance Law and Alternative Dispute Resolution, reflecting growing legal needs across corporate, risk and strategic advisory services.

Mr Greer said legal firms across Australia continue to demonstrate a commitment to professional distinction, with 700 firms represented this year and a record 500,000 evaluations made in the peer-review process required for nominees.

“Best Lawyers’ recognition process is a key indicator of legal expertise and credibility for clients and the broader legal profession, providing valuable third-party validation in a highly competitive industry.

“Our peer rankings provide a confirmed network for people to tap into and know they are getting the best legal representation,” he said.

Further strengthening its position in the Australian legal market, Best Lawyers will announce the 2026 Best Law Firms™ – Australia and release its Australian Legal Market Report providing a comprehensive overview of legal trends on May 29, 2025.

Search The Best Lawyers in Australia and Best Lawyers: Ones to Watch in Australia results by lawyer name, firm, region and/or practice area by visiting www.bestlawyers.com.

About Best Lawyers^®

Best Lawyers^® is the most established global network of legal professionals, providing elite lawyers and law firms with tools to enhance visibility, credibility and client engagement. Built on a rigorous peer-review process, Best Lawyers delivers data-driven legal recognition while offering industry insights and tech-forward marketing solutions. Powering Best Law Firms®, we simplify the law firm selection process, fostering confidence between firms and clients. Learn more at www.bestlawyers.com and www.bestlawfirms.com.

Australian Media Contacts:

US-based Contact:

Alliccia Odeyemi
Senior Public Relations Manager
aodeyemi@bestlawyers.com

¹ The number of honored individuals divided by 90,000 lawyers practicing (as reported by Statista).

Photo – https://laotiantimes.com/wp-content/uploads/2025/04/best_lawyers__2026_editions_of_the_best_lawyers_in_australia.jpg

Logo – https://laotiantimes.com/wp-content/uploads/2025/04/best_lawyers_logo.jpg 

PARIS, April 17, 2025 /PRNewswire/ — On the second day of an official visit to France, His Excellency Fahad Abdulrahman AlJalajel, Minister of Health of the Kingdom of Saudi Arabia, held bilateral meetings with senior French officials including Minister for Labour, Health, Solidarity and Families Catherine Vautrin, Minister for Health and Access to Care Yannick Neuder and Laurent Saint-Martin, Minister Delegate for Foreign Trade and French Nationals Abroad.

During a three-day official visit to France, His Excellency Fahad Abdulrahman AlJalajel, Minister of Health of the Kingdom of Saudi Arabia, held bilateral meetings with senior French officials, including Catherine Vautrin, Minister for Labour, Health, Solidarity, and Families

Discussions focused on strengthening cooperation in health innovation, research, workforce development, investment promotion, and supply chain resilience, aligned with the Kingdom’s Vision 2030 Health Sector Transformation.

A highlight of the visit was the signing of several agreements, witnessed by Their Excellencies, designed to strengthen and expand the health partnership between Saudi Arabia and France. The first between Seha Virtual Hospital and Gustave Roussy aims to enhance cancer care and digital health through AI-powered telemedicine.

Another, signed between the Health Holding Company (HHC) and France Biotech, focuses on accelerating the development of the Health Tech and Life Sciences ecosystems in both countries by supporting healthcare startups and promoting the integration of innovative technologies.

A third agreement, between the Saudi Red Crescent Authority and Assistance publique-hôpitaux de Paris, will strengthen cooperation in Emergency Medical Services, including joint training, knowledge exchange, and best practices in emergency response.

His Excellency Minister Aljalajel stated: “I welcome the strengthening of these collaborative ties with France’s leading institutions, which reflect our commitment to advancing excellence and innovation across the health sector. These partnerships not only strengthen international ties but also position the Kingdom of Saudi Arabia as a dynamic and innovation-friendly ecosystem – one that is actively attracting global innovators and creating significant opportunities for transformative impact within our evolving healthcare landscape. They represent an important step forward in achieving the goals of Vision 2030, as we continue to transform our health system to deliver world-class care and foster a thriving life sciences sector.”

The Minister’s three-day visit to Paris and Lyon demonstrates the shared commitment of Saudi Arabia and France to enhance healthcare services and innovation, while further strengthening their bilateral relationship in support of global health goals.

HO CHI MINH CITY, Vietnam, April 17, 2025 /PRNewswire/ — Amid Southeast Asia’s fast-evolving real estate and hospitality landscape, industry leaders are coming together in Bangkok for an evening that blends insight, strategy and high-impact networking. HoSkar Night Bangkok 2025 will take place on 8 May at the prestigious Dusit Thani Bangkok, bringing together a curated group of influential leaders from across the region.

Organized by WeHub, this exclusive event will welcome real estate developers, hotel owners, architects, operators and investment partners for a high-impact evening centered on networking, insights and opportunity.

Whether you’re an established industry leader or a rising innovator, HoSkar Night offers a rare opportunity to gain insights, make meaningful connections and shape the future of real estate and hospitality in the region. With a handpicked guest list and a dynamic atmosphere, this event goes beyond typical networking – it’s where Asia’s next big ideas are born.

Developer Seminar: Ultra-Luxury Branded Residences

The event will commence with an in-depth seminar focused on the future of branded residences. Featuring leading voices from Savills UK, Savills Thailand, Brand&Co, CMV Architects, HotStats, Dusit International, Minor Hotels and Accor, this session will address global and regional trends in branded residential developments, mixed-use project integration, operating performance, brand positioning and cost strategy. The seminar will blend case studies, data insights and panel discussions for a comprehensive industry overview.

HoSkar Night Networking Session

Following the seminar, attendees will be invited to an evening of professional networking session. Designed to foster meaningful dialogue and facilitate valuable business introductions, the HoSkar Night session provides an intimate and sophisticated environment to engage with industry peers and explore potential collaborations.

Participation and Registration

Due to limited capacity, we will be implementing a “First-register, first-served” policy, with priority given to selected categories. Entry is exclusively granted with the confirmation email from the WeHub Team. Inquire now to join the HoSkar Night in Bangkok on 8th May: https://hoskarnight.com/registration-bangkok/

Strategic Partners and Supporters

HoSkar Night Bangkok 2025 is supported by a distinguished network of partners, including Brand&Co, CMV Architects, Savills, Dusit International and Atlas Concorde, with additional collaboration from Accor, Meinhardt, Archetype Group, Delivering Asia and PR Newswire.

Regional Event Series 2025

Following Bangkok, HoSkar Night will continue its Asia-Pacific series in Phnom Penh (4 June), Ho Chi Minh City (10 July), Hanoi (1 October), Manila (23 October) and Dubai (November).

For press inquiries or partnership opportunities, please contact: host@wehubyou.com.

Vision Asia Pacific is a registered company which owns WeHub and organizes multiple event series, including the Meet The Experts conference (MTE) and the HoSkar Night networking event, serving the real estate and hospitality industries across Asia.